Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Up 2.3 %

Shares of CYCC opened at $1.79 on Wednesday. Cyclacel Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $13.20. The business’s fifty day moving average is $2.33 and its 200 day moving average is $3.89. The stock has a market cap of $2.36 million, a P/E ratio of -0.07 and a beta of 0.54.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The firm had revenue of $0.03 million during the quarter. On average, analysts expect that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.